Stripe's @RuxandraTeslo on why today's Moderna Phase 3 melanoma win probably won't hold in lung cancer or other solid tumors: "People are betting on Moderna's platform, so they expect these results won't just hold in skin cancer. They will also repeat themselves in other types of solid cancer, for example lung cancer. That might happen or it might not happen." "Skin cancer is the ideal cancer for cancer vaccines because it has this very high mutational burden, which allows the immune system to recognize the tumor very well. It's the cancer that responds so well to all immunotherapies." "Here we have seen the most bullish cancer, the best cancer for this type of vaccine. I'm excited about results in the future, but that is a big caveat, that we've seen the most favorable terrain in which these vaccines could be tested." @WorksInProgMag @stripe